GGrantIndex
← Search

PHARMACOKINETICS OF NSC 655649 SEQUENCES AND CISPLATIN

$0M01FY2000RRNIH

University Of Texas Hlth Sci Ctr San Ant, San Antonio TX

Investigators

Linked publications & trials

Abstract

NSC 655649, a topoisomerase II inhibitor, has demonstrated activity against a range of tumors. Based on observed synergies between platinum compounds and other topoisomerase II inhibitors, a rationale exists to test NSC 655649 in combination with cisplatinum. This study will determine the effect of sequencing the drugs on toxicities, determine the pharmacokinetics, and assess any anti-tumor effects.

View original record on NIH RePORTER →